Related news from
Wed, 29 Jul 2026 12:29:02 +0000	Hercules Capital Earnings: What To Look For From HTGC Specialty finance company Hercules Capital (NYSE:HTGC) will be announcing earnings results this Thursday after market close. Here’s what to look for.
Tue, 28 Jul 2026 10:00:00 +0000	Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026 SAN MATEO, Calif., July 28, 2026--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a second quarter 2026 total cash distribution of $0.47 per share. The following shows the key dates of the
Fri, 24 Jul 2026 20:05:00 +0000	Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031 SAN MATEO, Calif., July 24, 2026--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the "Notes").
Wed, 22 Jul 2026 22:15:02 +0000	Hercules Capital (HTGC) Falls More Steeply Than Broader Market: What Investors Need to Know In the latest trading session, Hercules Capital (HTGC) closed at $15.93, marking a -1.24% move from the previous day.
Tue, 21 Jul 2026 20:15:00 +0000	Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031 SAN MATEO, Calif., July 21, 2026--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on July 24, 2026.
Thu, 16 Jul 2026 22:15:02 +0000	Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors The latest trading day saw Hercules Capital (HTGC) settling at $16.37, representing a +1.61% change from its previous close.
Thu, 16 Jul 2026 10:00:00 +0000	Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call SAN MATEO, Calif., July 16, 2026--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2026 financial results conference call for Thursday, July 30, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will
Wed, 15 Jul 2026 14:01:50 +0000	Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company’s Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases […]
Wed, 15 Jul 2026 13:32:00 +0000	PhenixFIN (PFX) Soars 7.4%: Is Further Upside Left in the Stock? PhenixFIN (PFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Thu, 09 Jul 2026 22:15:04 +0000	Hercules Capital (HTGC) Stock Dips While Market Gains: Key Facts Hercules Capital (HTGC) reached $15.69 at the closing of the latest trading day, reflecting a -1.26% change compared to its last close.
Tue, 07 Jul 2026 21:15:01 +0000	Saratoga Investment (SAR) Q1 Earnings and Revenues Miss Estimates Saratoga Investment (SAR) delivered earnings and revenue surprises of -12.96% and -2.82%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?
Sat, 04 Jul 2026 18:09:17 +0000	How Investors May Respond To Hercules Capital (HTGC) ESOP Equity Shelf And Potential Dilution Risk In late June 2026, Hercules Capital, Inc. filed a shelf registration to offer 14,000,000 shares of common stock, totaling US$213.36 million, for an ESOP-related offering. This move adds a potential new source of equity capital at a time when the company’s earnings per share have been weakening and leverage is elevated. Now we’ll examine how this new equity shelf, and the risk of dilution it implies, could reshape Hercules Capital’s investment narrative. The future of work is here. Discover...
Sat, 04 Jul 2026 13:41:09 +0000	Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
Fri, 03 Jul 2026 13:12:32 +0000	Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock’s inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next 12-months making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) one of the Best Rising Penny Stocks to Buy According […]
Fri, 03 Jul 2026 10:34:06 +0000	1 Financials Stock with Impressive Fundamentals and 2 We Find Risky Financial firms serve as the backbone of the economy, providing essential services from lending and investment management to risk management and payment processing. But uncertainty about fiscal and monetary policy has tempered enthusiasm, and over the past six months, the industry has pulled back by 1.3%. This drop was disheartening since the S&P 500 gained 8.4%.
Wed, 01 Jul 2026 12:17:00 +0000	3 Stocks Under $50 We Approach with Caution Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Mon, 29 Jun 2026 12:00:00 +0000	4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million. “Our strong cash, cash equivalents
Wed, 24 Jun 2026 13:30:05 +0000	Brokers Suggest Investing in Hercules Capital (HTGC): Read This Before Placing a Bet According to the average brokerage recommendation (ABR), one should invest in Hercules Capital (HTGC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Tue, 23 Jun 2026 12:24:46 +0000	2 Reasons to Avoid HTGC and 1 Stock to Buy Instead Over the past six months, Hercules Capital’s stock price fell to $15.30. Shareholders have lost 16.9% of their capital, which is disappointing considering the S&P 500 has climbed by 8.5%. This may have investors wondering how to approach the situation.
Wed, 17 Jun 2026 11:30:00 +0000	Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like BDCs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!